- Trials with a EudraCT protocol (436)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (478)
436 result(s) found for: Paracetamol.
Displaying page 22 of 22.
EudraCT Number: 2008-005048-17 | Sponsor Protocol Number: VRP080415 | Start Date*: 2009-01-27 | ||||||||||||||||
Sponsor Name:Verona Pharma Plc | ||||||||||||||||||
Full Title: A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics | ||||||||||||||||||
Medical condition: Allergic Asthma and Allergic Rhinitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002092-25 | Sponsor Protocol Number: 9766 | Start Date*: 2018-06-18 |
Sponsor Name:University Hospital of Montpellier | ||
Full Title: A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to l... | ||
Medical condition: Degenerative Disc Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Completed) DE (Trial now transitioned) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002486-39 | Sponsor Protocol Number: A0081128 | Start Date*: 2006-11-01 | |||||||||||
Sponsor Name:Pfizer Ltd, Ramsgate Road Sandwich, UK | |||||||||||||
Full Title: A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN. | |||||||||||||
Medical condition: Treatment of moderate to severe chronic bone pain related to metastatic cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Completed) IT (Prematurely Ended) FR (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021184-32 | Sponsor Protocol Number: GP13-201/GPN013A2301 | Start Date*: 2010-11-30 | |||||||||||
Sponsor Name:Hexal AG | |||||||||||||
Full Title: A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolera... | |||||||||||||
Medical condition: Refractory rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Completed) AT (Completed) IT (Completed) BE (Completed) EE (Completed) HU (Completed) PL (Completed) BG (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004226-15 | Sponsor Protocol Number: Can-Art1 | Start Date*: 2018-10-26 | ||||||||||||||||
Sponsor Name:King Christian 10th Hospital for Rheumatology | ||||||||||||||||||
Full Title: CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A rand... | ||||||||||||||||||
Medical condition: Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002055-42 | Sponsor Protocol Number: TV48125CNS30083 | Start Date*: 2021-01-07 | ||||||||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for ... | ||||||||||||||||||
Medical condition: Episodic Migraine | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FI (Completed) PL (Completed) NL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002579-12 | Sponsor Protocol Number: CLL2222 | Start Date*: 2023-04-04 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: Front-Line Venetoclax and Obinutuzumab combination followed by Venetoclax or Venetoclax and Zanubrutinib combination in patients with residual disease: a minimal residual disease (MRD) tailored tre... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002053-33 | Sponsor Protocol Number: TV48125CNS30082 | Start Date*: 2021-01-07 | ||||||||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for ... | ||||||||||||||||||
Medical condition: Chronic Migraine | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FI (Completed) NL (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002335-17 | Sponsor Protocol Number: 2015-602295-01 | Start Date*: 2015-11-30 | |||||||||||
Sponsor Name:Ethicare GmbH | |||||||||||||
Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN CHILDREN WITH HEART FAILURE DUE TO DILATED CARDIOMYOPATHY | |||||||||||||
Medical condition: Heart Failure due to Dilated Cardiomyopathy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002126-36 | Sponsor Protocol Number: BP39261 | Start Date*: 2017-03-01 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multi-center, three-part phase II study to evaluate the safety and efficacy of RO7123520 as adjunct treatment in patients with moderately to severely... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002396-18 | Sponsor Protocol Number: 2015-602295-02 | Start Date*: 2015-11-30 | |||||||||||
Sponsor Name:Ethicare GmbH | |||||||||||||
Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE | |||||||||||||
Medical condition: Heart Failure due to Congenital Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006226-49 | Sponsor Protocol Number: NN6019-4940 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM) | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (ATTR CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003812-36 | Sponsor Protocol Number: MORAb-003-011 | Start Date*: 2015-06-30 | |||||||||||
Sponsor Name:Morphotek Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegyl... | |||||||||||||
Medical condition: Serious epithelial ovarian cancer including primary peritoneal and fallopian tube malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004148-49 | Sponsor Protocol Number: B5371002 | Start Date*: 2014-07-14 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID A... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) CZ (Completed) GB (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013329-41 | Sponsor Protocol Number: A4091030 | Start Date*: 2010-01-12 | ||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: ESTUDIO EN FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO Y OXICODONA PARA DETERMINAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN PACIENTES CON ARTROSIS DE RODILLA O CAD... | ||||||||||||||||||
Medical condition: ARTROSIS DE RODILLA Y CADERA osteoarthritis of the knee and hip | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) SE (Completed) DE (Completed) AT (Completed) DK (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000296-36 | Sponsor Protocol Number: ZWI-ZW25-301 | Start Date*: 2021-11-17 | ||||||||||||||||
Sponsor Name:Zymeworks Inc. | ||||||||||||||||||
Full Title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gast... | ||||||||||||||||||
Medical condition: Gastroesophageal Adenocarcinoma (GEA) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
